ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Ajay K. Nooka, MD Source Type: news